CD22

Synonyms

B-Lymphocyte Cell Adhesion Molecule, SIGLEC2, BL-CAM, Siglec-2, Sialic Acid Binding Ig-like Lectin 2, B-cell receptor CD22, Sialic acid-binding Ig-like lectin 2, T-cell surface antigen Leu-14, CD22, CD22 Molecule, CD22 Antigen

Description

Mediates B-cell B-cell interactions. May be involved in the localization of B-cells in lymphoid tissues. Binds sialylated glycoproteins; one of which is CD45. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site can be masked by cis interactions with sialic acids on the same cell surface. Upon ligand induced tyrosine phosphorylation in the immune response seems to be involved in regulation of B-cell antigen receptor signaling. Plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules.

KO Status

RenMab: In Vitro

RenLite: F0

Drug Information

Launched drugs: 2
Drugs in clinical trials: 37
Latest Research Phase: Approved

Drug Name

Code

Phase

Company

Indications

Clinical Trials

Inotuzumab Ozogamicin

CMC-544, WAY-207294, PF-5208773

Approved

Pfizer Inc, Ucb

Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma

Moxetumomab pasudotox

HA-22, CAT-8015, GCR-8015

Approved

Astrazeneca Plc

Leukemia, Hairy Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

Epratuzumab

AMG-412, CDP-3194, IMMU-103, IMMU-1903, IMMU-hLL2

Phase 3 Clinical

Immunomedics Inc

Lymphoma, B-Cell, Sjogren's Syndrome, Lupus Erythematosus, Systemic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin

SM-03

SM-03, SM-06

Phase 3 Clinical

Lonn Ryonn Pharma Ltd, Sinomab Bioscience Ltd

Arthritis, Rheumatoid, Lupus Erythematosus, Systemic, Lymphoma, Non-Hodgkin

Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital)

Phase 2 Clinical

People'S Liberation Army General Hospital Military Service

Leukemia, Lymphoma

4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute)

4SCAR-T

Phase 2 Clinical

Shenzhen Geno-Immune Medical Institute

Neoplasms

CD19/CD22 bispecific CAR-T (Zhejiang University)

Phase 2 Clinical

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Anti-CD22-CAR T cell therapy (Kecellitics Biotech)

Phase 2 Clinical

Kecellitics Biotech Company Ltd

Leukemia, Lymphoma

Dual specificity CD19 and CD20 or CD22 CAR-T cell (Chinese PLA General Hospital)

Phase 2 Clinical

Pla General Hospital

Leukemia, Lymphoma, B-Cell

Anti-CD22 CAR-T cell therapy (iCarTAB BioMed)

Phase 2 Clinical

Aikangd Biomedical Technology (Suzhou) Co Ltd

Lymphoma, B-Cell

References


Title

Authors

Source

The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)

The MGC Project Team,

Genome Res. 14:2121-2127(2004)

Identification of the gene variations in human CD22

Hatta Y., Tsuchiya N., Matsushita M., Shiota M., Hagiwara K., Tokunaga K.,

Immunogenetics 49:280-286(1999)

Natural ligands of the B cell adhesion molecule CD22 beta carry N-linked oligosaccharides with alpha-2,6-linked sialic acids that are required for recognition

Powell L.D., Sgroi D., Sjoberg E.R., Stamenkovic I., Varki A.,

J. Biol. Chem. 268:7019-7027(1993)

A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP

Doody G.M., Justement L.B., Delibrias C.C., Matthews R.J., Lin J., Thomas M.L., Fearon D.T.,

Science 269:242-244(1995)

Involvement of p72syk kinase, p53/56lyn kinase and phosphatidyl inositol-3 kinase in signal transduction via the human B lymphocyte antigen CD22

Tuscano J.M., Engel P., Tedder T.F., Agarwal A., Kehrl J.H.,

Eur. J. Immunol. 26:1246-1252(1996)

CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma(1) upon B cell activation

Law C.L., Sidorenko S.P., Chandran K.A., Zhao Z., Shen S.H., Fischer E.H., Clark E.A.,

J. Exp. Med. 183:547-560(1996)

CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling

Tedder T.F., Tuscano J., Sato S., Kehrl J.H.,

Annu. Rev. Immunol. 15:481-504(1997)

Uncovering global SUMOylation signaling networks in a site-specific manner

Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M., Vertegaal A.C.,

Nat. Struct. Mol. Biol. 21:927-936(2014)

The B-cell antigen CD22 mediates monocyte and erythrocyte adhesion

Stamenkovic I., Seed B.,

Nature 345:74-77(1990)

cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions

Wilson G.L., Fox C.H., Fauci A.S., Kehrl J.H.,

J. Exp. Med. 173:137-146(1991)